R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
Study Details
Study Description
Brief Summary
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of R-CHOP (Rituximab-Cyclophosphamide, Epirubicin, Vincristine and Prednisone) combined with lenalidomide in the first-line treatment for patients with medium to high risk/high risk diffuse large B cell lymphoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 2 |
Detailed Description
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL). Currently, R-CHOP is world-widely used in the first-line treatment for DLBCL. There are about one second of patients suffering relapse and drug resistance. Lenalidomide is an analog of thalidomide, the mechanism of anti-tumor action has not been fully elucidated. Lenalidomide has been proved to inhibit the proliferation of tumor cells in certain hematopoietic systems. At present, it has been approved for the treatment of multiple myeloma with good efficacy and safety. The goal of our trial is to assess the efficacy and safety of R-CHOP combined with lenalidomide in the first-line treatment for patients with medium to high risk/high risk diffuse large B cell lymphoma.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: R-CHOP regimen Combined With Lenalidomide Induction Chemotherapy: Rituximab, 375mg/m2, Intravenous administration on day 0, Lenalidomide, 25mg oral administration on day 1 to 10, combined with regimen:CHOP (Cyclophosphamide, Epirubicin, Vincristine and Prednisone): repeated every 3 weeks, up to 6 cycles. PS: Methotrexate, 3mg/m2, Intravenous administration on day 3 of each 3-week cycle, from 2 to 5 cycles for patients with high recurrence risk of the central nervous system. Maintenance Treatment: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 4 weeks, up to 2 cycles; Lenalidomide, 10mg oral administration on day 1 to 21 repeated every 4 weeks, up to 12 cycles. |
Drug: Rituximab
Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Maintenance Treatment: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles.
Other Names:
Drug: Lenalidomide
Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Maintenance Treatment: 10mg oral administration on day 1 to 21 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 12 cycles.
Other Names:
Drug: Cyclophosphamide
Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Other Names:
Drug: Epirubicin
Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Other Names:
Drug: Vincristine
Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Other Names:
Drug: Prednisone
Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Other Names:
Drug: Methotrexate
Induction Chemotherapy: 3mg/m2, Intravenous administration on day 3 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- 2-year progression-free survival [from the day of the first cycle of treatment to the date of confirmed progressive disease or death, whichever occurs first, up to 2 years after last patient's enrollment]
the total proportion of patients with no progression from date of the first day of treatment to the date of confirmed progressive disease or death which one occurs first
Secondary Outcome Measures
- objective response rate [every 6 weeks from the day of the first cycle of induction chemotherapy treatment and every 8 weeks from the day of the first cycle of maintenance treatment to 18 months after last patient's enrollment]
the total proportion of patients with complete response (CR) and partial response (PR)
- 2-year overall survival [from date of the first cycle of treatment to the date of death from any cause, assessed up to 2 years]
from date of first day of treatment to the date of death by any cause
- incidence and relationship with study drugs of grade 3-4 adverse events [from the date of the first cycle of treatment to 18 months after last patient's enrollment]
the incidence and relationship with study drugs of grade 3 or 4 adverse events (based on NCI CTC-AE v4.03)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age between 18 to 70 years old (including 18 and 70)
-
Diagnosed as diffuse large B cell lymphoma
-
Subjects must be untreated (medium to high risk/high risk: International Prognostic Index (IPI) score 3-5, aaIPI score 2-3 or NCCN-IPI score≥ 4/ Immunohistochemical staining of double expression (BCL2 ≥ 70% and C-MYC ≥ 40%) or P53 protein mutation positive ≥ 50%)
-
No receiving chemotherapy before enrollment
-
Having at least one measurable lesions
-
World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) 0-1
-
Life expectancy no less than 3 months
-
enough main organ function
-
Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study
-
Agreeing to sign the written informed consents
Exclusion Criteria:
-
Diagnosed as high-grade B-cell lymphoma, including non-specified and double-strike or triple-strike
-
Diagnosed as grey-zone lymphoma
-
Diagnosed as central nervous system lymphoma
-
Diagnosed as primary mediastinal large B-cell lymphoma
-
Diagnosed as CD20 negative diffuse large B-cell lymphoma
-
Other malignant tumor history or active malignant tumor need be treated
-
Serious surgery and trauma less than two weeks
-
Systemic therapy for serious acute/chronic infection
-
Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months
-
Vaccination with live attenuated vaccine less than 4 weeks
-
HIV-positive, AIDS patients and untreated active hepatitis
-
Patients with a history of deep vein thrombosis or pulmonary embolism less than 12 months
-
Patients with a history of mental illness
-
Researchers determine unsuited to participate in this trial
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university | Zhengzhou | Henan | China |
Sponsors and Collaborators
- Henan Cancer Hospital
Investigators
- Study Director: Yanyan Liu, M.D. Ph.D, Henan Cancer Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HNSZLYYNHL02